If GLP-1 worsens IBS significantly, stopping or switching to an alternative is appropriate
If you have any questions in the meantime, don't hesitate to reach out
In this guide, you will learn exactly how Retatrutide and Tirzepatide differ, what the latest clinical evidence says about their efficacy, and how to choose the right compound for your specific research goals when sourcing supplies from a premium provider like Just Peptides Lab
No, never take a double dose to catch up. This can cause a sharp increase in side effects like nausea
Clinical Evidence: What the Data Shows Phase 3 Trial Results (Zepbound Studies) The REFRAME and related trials demonstrated: Weight Loss Average: 22.5% body weight reduction at 68 weeks Range: 18-28% depending on population Significantly exceeds tirzepatide (21% at comparable doses) Body Composition Preferential loss of visceral fat (the dangerous kind) Better preservation of lean muscle vs
This article examines the relationship between GLP-1 therapy and blood pressure management in UK clinical practice
